Top Tweets for #ComCov
@PeachesTweets @ResearchNBT @NorthBristolNHS Bravo Lord Lieutenant of Bristol @PeachesTweets for volunteering to help medical studies in the #COMCOV vaccine trial @NorthBristolNHS Hopefully the study will assist in better health protection for all.
I have now completed the #COMCOV vaccine trial, helped throughout by Nurse Liz Barnett at @ResearchNBT Hopefully the knowledge gained from the study will positively influence medical choices procedures worldwide.
Get your #boostershot for #COVID19 & #flujab
@NorthBristolNHS
Thank you so much Matthew Snape & @PlestedEmma for giving interesting insight in the COMCOV studies @OxfordVacGroup and Zoi Pana for her professional moderation of our #COMCOV vaccine trials webinar. The webinar will be online soon in case you missed it! #VaccinesSaveLives
#COMCOV #clinicaltrial #webinar TODAY! Registration still possible. Get updated on #COVID19 vaccine trials with Matthew Snape and #VACCELERATE.
Heterologous prime-boosting, mRNA -> adenovirus vaccine:
#COMCOV preprint data indicates that 1 dose #Astrazeneca ("ChAd") followed by 1 dose #Pfizer ("BNT") produces an immune response similar to that induced by 2 doses of Pfizer's mRNA COVID-19 vaccine.
https://t.co/SbFN6oM0Wg
Registration possible now for #COVID19 #COMCOV #webinar: https://t.co/P90VzJxbg4
#VaccinesSaveLives 💉
#COMCOV VACCINE TRIALS WEBINAR
September 15 14:00 CEST
by #VACCELERATE Matthew Snape @PlestedEmma @OxfordVacGroup @UniofOxford @EU_Commission @HorizonEU
Studies, goals, vaccination reactions, effectiveness, timing.
Registration from Sep 8: https://t.co/hU123GA317
#COMCOV VACCINE TRIALS WEBINAR
September 15 14:00 CEST
by #VACCELERATE Matthew Snape @PlestedEmma @OxfordVacGroup @UniofOxford @EU_Commission @HorizonEU
Studies, goals, vaccination reactions, effectiveness, timing.
Registration from Sep 8: https://t.co/hU123GA317
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - @TheLancet #ComCOV https://t.co/2Yytewwarg
@MyCombiVac Why so little publicity for the #ComCov and #ComCov2 trials? Surely valuable data for booster vax policy and to win over the vaccine-hesitant?
The @OxfordVacGroup’s Com-Cov vaccine trial is studying the use of different combinations of approved #COVID19 vaccines for the first and second immunisation doses.
More on the #ComCov study: https://t.co/b59IOQv8tA
#CovidVaccine #COVIDVaccination #VaccinesWork
Primer estudio que analiza todas las combinaciones posibles entre las vacunas de Pfizer y de AstraZeneca da resultados que avalan el intercambio de estas vacunas. (Estudio #ComCOV de Oxford, en revisión de pares ahora mismo para publicación en The Lancet).
https://t.co/aeXElHNsgQ
El estudio #ComCov demuestra una robusta respuesta inmunitaria cuando se utiliza la pauta #Vaxzevria /#Comirnaty
Pasos de evidencia científica hacia el uso de #VacunaCOVID19 heteróloga
Preprint:
🔗 https://t.co/bgXNqRkVfb
SARS-CoV-2: Wechsel des Impfstoffs kann Immunität verbessern: Oxford – Erwachsene, die nach dem Astrazeneca-Impfstoff Vaxzevria als 2. Dosis die Biontech/Pfizer-Vakzine Comirnaty erhielten,… https://t.co/4F0IqvkGLh #Studie #ComCOV #Lancet #COVID19 #heterologeImpfung
Combinar vacunas mejora la inmunidad?! Se acaban de publicar los esperadísimos resultados del estudio #ComCov 🇬🇧
Os doy las claves en este vídeo https://t.co/yI1nL2fHvh
#ComCov Study: Specific mixing of vaccines gives higher Covid protection:
“An #AstraZeneca-#Pfizer combination induced higher antibody and T-cell responses than the Pfizer-AstraZeneca combination.”
https://t.co/KtPYYO1WG1
BREAKING NEWS: Oxford study says mixing COVID-19 vaccines gives good protection https://t.co/QRcwzryH6H #ComCOV #Covid19 #MixAndMatch #OxfordStudy #vaccines
@iamkapilan @SriLankaTweet #COMCOV was done on people >50 & now there is a general tendency in the west to offer everyone a mRNA vaccine as 2nd dose.
If you weigh the S/E vs benefit, it makes sense to offer our elderly the mix as well.
But there will be a supply problem
Final call by @MoH_SriLanka
@SJisMe @OxfordVacGroup Great question.
The same #COMCOV study is looking at a 12 week dosing interval as well.
Results should be out in August.
@iamkapilan @SriLankaTweet @BBCWorld No, the mixing trial of #COMCOV showed that AZ/Pfizer has a much better immune response than AZ/AZ. So no need of a restart.
But a booster trial is also going on. #COVBOOST, which looks at a 3rd dose of Pfizer/AZ/Moderna/Novavax/Valneva/CureVac/J&J
https://t.co/SEJuYFLguV
1st dose #AstraZeneca
2nd dose #Pfizer
4 week interval, n=463
AZ/Pfizer mix produced antibodies X9 as much as AZ/AZ
*Pfizer/Pfizer produced best Ab response overall but highest T cell response was in mix
#COMCOV study @OxfordVacGroup
#VaccinatedSL https://t.co/mAitsZzEBg
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers